TScan Therapeutics reported a net margin of -2,888.58% for the quarter ended Jun 2026. These financial ratios cover 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||||||||||||||
| EBT Margin | -656.67% | -497.55% | -534.79% | -372.21% | -483.05% | -604.94% | -331.66% | -763.82% | -591.64% | -271.99% | -5,325.44% | -5,906.90% | -2,849.09% | -5,220.90% | -1,571.95% | -1,201.30% | -1,422.14% | -895.09% | -2,919.14% | -2,888.58% | ||||
| EBIT Margin | -656.80% | -497.62% | -535.02% | -375.89% | -492.95% | -602.55% | -334.31% | -781.77% | -636.69% | -296.17% | -5,542.93% | -6,364.55% | -3,109.82% | -5,520.60% | -1,669.74% | -1,256.60% | -1,475.59% | -929.41% | -2,967.31% | -2,901.33% | ||||
| EBITDA Margin | -656.80% | -497.62% | -535.02% | -375.89% | -492.95% | -602.55% | -334.31% | -781.77% | -636.69% | -296.17% | -5,542.93% | -6,364.55% | -3,109.82% | -5,520.60% | -1,669.74% | -1,256.60% | -1,475.59% | -929.41% | -2,967.31% | -2,901.33% | ||||
| Operating Margin | -656.80% | -497.62% | -535.02% | -375.89% | -492.95% | -602.55% | -334.31% | -781.77% | -636.69% | -296.17% | -5,542.93% | -6,364.55% | -3,109.82% | -5,520.60% | -1,669.74% | -1,256.60% | -1,475.59% | -929.41% | -2,967.31% | -2,901.33% | ||||
| Net Margin | -656.67% | -497.55% | -534.79% | -372.21% | -483.05% | -604.94% | -331.66% | -763.82% | -591.64% | -271.99% | -5,325.44% | -5,906.90% | -2,849.09% | -5,220.90% | -1,571.95% | -1,201.30% | -1,422.14% | -895.09% | -2,919.14% | -2,888.58% | ||||
| FCF Margin | -600.87% | -581.32% | -683.71% | -376.23% | -518.17% | -561.78% | -359.03% | -712.90% | 169.75% | -336.08% | -5,295.41% | -5,053.54% | -2,791.99% | -4,255.64% | -1,801.84% | -1,123.08% | -1,349.62% | -1,253.33% | -2,479.53% | -2,666.79% | ||||
| Efficiency | ||||||||||||||||||||||||
| Assets AverageAssets Avg. | 167.45M | 196.50M | 178.16M | 160.31M | 158.93M | 182.27M | 186.33M | 245.25M | 304.15M | 281.76M | 256.49M | 307.85M | 361.45M | 359.57M | 351.91M | 315.63M | 280.39M | 245.51M | 215.39M | 186.72M | ||||
| Invested CapitalInvested Cap. | 145.73M | 128.72M | 107.52M | 220.33M | 198.91M | 180.91M | 153.21M | 285.67M | 259.73M | 273.04M | 242.38M | 209.01M | 176.44M | 155.66M | 129.58M | 101.80M | ||||||||
| Asset Utilization RatioAsset Util. | 0.05 | 0.05 | 0.06 | 0.08 | 0.08 | 0.07 | 0.09 | 0.07 | 0.06 | 0.07 | 0.06 | 0.04 | 0.03 | 0.01 | 0.01 | 0.02 | 0.03 | 0.04 | 0.04 | 0.04 | ||||
| Leverage & Solvency | ||||||||||||||||||||||||
| Interest Coverage RatioInterest Cover | -82.48 | -19.13 | -23.79 | -25.40 | -25.20 | -25.07 | -32.71 | -35.83 | -34.05 | -46.83 | -53.39 | -56.10 | -53.01 | -33.99 | -42.29 | -43.62 | ||||||||
| Debt Ratio | 0.18 | 0.15 | 0.17 | 0.09 | 0.10 | 0.11 | 0.13 | 0.08 | 0.09 | 0.09 | 0.10 | 0.11 | 0.12 | 0.14 | 0.16 | 0.19 | ||||||||
| Times Interest Earned | -82.48 | -19.13 | -23.79 | -25.40 | -25.20 | -25.07 | -32.71 | -35.83 | -34.05 | -46.83 | -53.39 | -56.10 | -53.01 | -33.99 | -42.29 | -43.62 | ||||||||
| Valuation | ||||||||||||||||||||||||
| Price to EarningsP/E | -10.47 | -3.70 | -4.16 | -5.01 | -4.52 | -1.99 | -2.25 | -4.91 | -10.56 | -19.50 | -24.99 | -20.96 | -19.78 | -9.81 | -5.24 | -5.09 | -6.62 | -5.65 | -4.58 | -4.19 | ||||
| Price to SalesP/S | 68.72 | 18.39 | 22.22 | 18.66 | 21.83 | 12.04 | 7.48 | 37.49 | 62.46 | 53.04 | 0.00M | 0.00M | 563.52 | 511.96 | 82.43 | 61.15 | 94.11 | 50.56 | 133.62 | 121.17 | ||||
| Price to BookP/B | 0.95 | 0.33 | 0.46 | 0.57 | 0.63 | 0.37 | 0.65 | 0.62 | 1.44 | 2.53 | 6.13 | 2.60 | 2.58 | 1.41 | 0.85 | 1.06 | 1.64 | 1.05 | 1.35 | 1.85 | ||||
| Enterprise Value | -16.55M | -108.92M | -73.71M | -49.92M | -63.88M | -82.75M | -44.73M | -90.82M | 27.34M | 190.40M | 590.53M | 365.86M | 320.01M | 50.34M | -72.73M | -29.94M | 51.85M | -22.63M | 3.16M | 27.15M | ||||
| EV to EBIT | 1.04 | 7.67 | 4.56 | 3.27 | 3.85 | 4.44 | 1.97 | 3.69 | -1.10 | -8.92 | -18.82 | -10.72 | -9.81 | -1.37 | 2.01 | 0.77 | -1.40 | 0.95 | -0.11 | -0.89 | ||||
| EV to EBITDA | 1.04 | 7.67 | 4.56 | 3.27 | 3.85 | 4.44 | 1.97 | 3.69 | -1.10 | -8.92 | -18.82 | -10.72 | -9.81 | -1.37 | 2.01 | 0.77 | -1.40 | 0.95 | -0.11 | -0.89 | ||||
| Market Capitalization | 165.76M | 52.48M | 67.13M | 75.68M | 73.43M | 37.27M | 50.87M | 118.02M | 242.76M | 382.45M | 753.31M | 663.54M | 591.13M | 340.45M | 178.96M | 188.11M | 236.30M | 129.78M | 131.21M | 127.35M | ||||
| Price to FCFP/FCF | -11.44 | -3.16 | -3.25 | -4.96 | -4.21 | -2.14 | -2.08 | -5.26 | 36.79 | -15.78 | -25.13 | -24.50 | -20.18 | -12.03 | -4.57 | -5.45 | -6.97 | -4.03 | -5.39 | -4.54 | ||||
| EV to FCF | 1.14 | 6.57 | 3.57 | 3.27 | 3.67 | 4.76 | 1.83 | 4.05 | 4.14 | -7.86 | -19.70 | -13.51 | -10.93 | -1.78 | 1.86 | 0.87 | -1.53 | 0.70 | -0.13 | -0.97 | ||||
| EV to CFO | 1.21 | 7.57 | 3.66 | 3.73 | 3.76 | 5.17 | 1.90 | 4.12 | 3.41 | -8.01 | -20.18 | -13.95 | -11.46 | -1.84 | 1.94 | 0.90 | -1.60 | 0.71 | -0.13 | -0.99 | ||||
| Return Ratios | ||||||||||||||||||||||||
| Return on Sales [ROS]ROS | -656.80% | -497.62% | -535.02% | -375.89% | -492.95% | -602.55% | -334.31% | -781.77% | -636.69% | -296.17% | -5,542.93% | -6,364.55% | -3,109.82% | -5,520.60% | -1,669.74% | -1,256.60% | -1,475.59% | -929.41% | -2,967.31% | -2,901.33% | ||||
| Return on Capital Employed [ROCE]ROCE | -29.24% | -27.77% | -35.62% | -42.93% | -43.69% | -40.39% | -42.50% | -39.30% | -33.49% | -37.09% | -45.37% | -41.44% | -35.90% | -41.66% | -43.37% | -50.73% | -59.19% | -59.88% | -65.86% | -77.39% | ||||
| Return on Assets [ROA]ROA | -25.22% | -24.75% | -31.92% | -38.23% | -38.82% | -36.33% | -38.98% | -33.26% | -29.04% | -31.66% | -37.74% | -33.92% | -30.79% | -35.16% | -37.05% | -42.99% | -50.47% | -52.86% | -57.71% | -63.04% |